Biolargo, INC Form 4 insider transactions

Kenneth Reay Code, Chief Science Officer and a Director of Biolargo, Inc., reported multiple transactions in common stock on September 30, 2026.

Dennis P Calvert, President and a Director of Biolargo, Inc., reported multiple transactions in common stock on September 30, 2026.

Dennis E Marshall, a Director of Biolargo, Inc., reported multiple transactions in common stock on September 30, 2026.

Jack B. Strommen, a Director of Biolargo, Inc., received 187,500 shares of common stock on September 30, 2026.

Christina Elaine Bray, a Director of Biolargo, Inc., received 234,375 shares of common stock on September 30, 2026.

Linda Park, a Director of Biolargo, Inc., received 234,375 shares of common stock on September 30, 2026.

BioLargo, Inc. reports a significant acquisition of common stock by Chief Science Officer Kenneth Reay, subject to a lock-up agreement tied to revenue or market capitalization milestones.

BioLargo, Inc. reports director Dennis P. Calvert acquired shares in exchange for reduced salary and expenses, with certain shares subject to a lock-up agreement.

Director Jack B. Strommen of BioLargo, Inc. acquired stock options valued at $15,000 as compensation for board services.

BIOLARGO, INC. reports that Director Linda Park was granted stock options as compensation for board services.

Christina Bray, a Director at BioLargo, Inc., was granted a stock option for services rendered as a board member.

BioLargo, Inc. director Dennis E. Marshall reports transactions involving stock options and beneficial ownership adjustments.

BioLargo, Inc. director Dennis E. Marshall reported a change in beneficial ownership, reflecting an option adjustment and the expiration of previously held options.

BioLargo, Inc. reports a transaction where Chief Science Officer Kenneth Reay acquired 69,444 shares of common stock.

BioLargo, Inc. director Jack B. Strommen was granted options to purchase 92,593 shares of common stock as compensation for board services.

BioLargo, Inc. director Christina Bray was granted options to purchase 115,741 shares of common stock as compensation for board services.

BioLargo, Inc. director Linda Park was granted 115,741 stock options as compensation for board services, exercisable at $0.162 per share.

BioLargo, Inc. Director Dennis E. Marshall was granted new stock options totaling 254,630 shares as compensation for services and to replace an expired option.

BioLargo, Inc. Chief Financial Officer Charles K. Dargan was granted 300,000 stock options as compensation for his role.

BioLargo director Dennis E. Marshall was granted new stock options as compensation for services and to replace an expired option.

BioLargo's Chief Science Officer, Kenneth Reay Code, acquired 54,803 shares of common stock at $0.1843 per share, increasing his beneficial ownership.

BioLargo's President and 10% owner, Dennis P. Calvert, acquired 130,222 shares of common stock at $0.1843 per share, reducing company debt for salary and expenses, with shares subject to a future lock-up.

BioLargo, Inc. Director Linda Park was granted 101,736 stock options as compensation for board services, exercisable at $0.1843 per share.

BioLargo, Inc. director Christina Bray received 101,736 stock options as compensation for her board services, exercisable at $0.1843 per share.

BioLargo Director Jack B. Strommen was granted 81,389 stock options as compensation for board services, exercisable at $0.1843 per share.

BioLargo's Chief Science Officer, Kenneth Reay Code, acquired 313,754 shares of common stock by converting salary and expense debt, subject to a lock-up agreement.

BioLargo's President and Director, Dennis P. Calvert, acquired 310,269 shares of common stock by converting salary and expense debt, with shares subject to a lock-up agreement tied to future company performance.

BioLargo Director Jack B. Strommen was granted 88,235 stock options with an exercise price of $0.17 as compensation for board services.

BioLargo director Linda Park received 110,294 stock options as compensation for her board services, exercisable at $0.17 per share.

BioLargo Director Christina Bray received 110,294 stock options as compensation for her board services, exercisable at $0.17 per share.